The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

Myelodysplastic syndromes (MDSs) belong to a group of clonal bone marrow malignancies. In light of the emergence of new molecules, a significant contribution to the understanding of the pathogenesis of the disease is the study of the B-cell CLL/lymphoma 2 (BCL-2) and the programmed cell death recept...

Full description

Bibliographic Details
Main Authors:	Bartłomiej Kuszczak, Tomasz Wróbel, Katarzyna Wicherska-Pawłowska, Justyna Rybka
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	myelodysplastic syndromes BCL-2 MCL-1 PD-1 PD-L1 BH3-mimetics
Online Access:	https://www.mdpi.com/1422-0067/24/5/4708

Similar Items

Selective Small Molecule Myeloid Cell Leukemia-1 (MCL-1) Inhibitors: Novel Agents in Cancer Therapy
by: Hoda Sobhy Ibrahim, et al.
Published: (2019-12-01)

Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors
by: Viacheslav V. Senichkin, et al.
Published: (2021-12-01)

Regulation of the Autophagic Bcl-2/Beclin 1 Interaction
by: Geert Bultynck, et al.
Published: (2012-07-01)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
by: David J. Mallick, et al.
Published: (2020-08-01)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
by: Anne Slomp, et al.
Published: (2018-11-01)

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic
by: Victor S. Lin, et al.
Published: (2020-11-01)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
by: Enyuan Shang, et al.
Published: (2020-08-01)

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
by: Lanqin Wu, et al.
Published: (2019-08-01)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
by: Maxime Jullien, et al.
Published: (2020-03-01)

BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response
by: Le Zhang, et al.
Published: (2021-04-01)

Upregulation of Mcl-1S Causes Cell-Cycle Perturbations and DNA Damage Accumulation
by: Alena Y. Streletskaia, et al.
Published: (2020-09-01)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
by: Jonathan R. Sillar, et al.
Published: (2019-10-01)

Regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer’s disease
by: Abdol-Hossein Rezaeian, et al.
Published: (2022-01-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment
by: Suxia Geng, et al.
Published: (2022-08-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative Breast Cancer MDA-MB-231 Cells
by: Giovanni Pratelli, et al.
Published: (2023-07-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
by: YUAN Ting, et al.
Published: (2021-10-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Sensitivity of Cutaneous T-Cell Lymphoma Cells to the Mcl-1 Inhibitor S63845 Correlates with the Lack of Bcl-w Expression
by: Uly Sumarni, et al.
Published: (2022-10-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
by: Ryan N. Rys, et al.
Published: (2021-02-01)

Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia
by: Matyas Meggyes, et al.
Published: (2019-01-01)

BCL-2 as therapeutic target for hematological malignancies
by: Guilherme Fleury Perini, et al.
Published: (2018-05-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)

Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer
by: Walter Douglas Fairlie, et al.
Published: (2021-03-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy
by: Yang Xicheng
Published: (2022-01-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)